Singapore's Biotech Corridor Boom: Early Movers Cash In as One-North Transforms into Asia's Innovation Powerhouse

The transformation of Singapore's One-North district into a dedicated biotech and advanced manufacturing hub is creating a cascade of opportunities for companies that got in early—and attracting waves of fresh capital to those still arriving.

Since the government earmarked the Buona Vista precinct for accelerated development in 2024, commercial property values within a 500-metre radius have climbed roughly 12 per cent, according to Jones Lang LaSalle's latest quarterly report. But the real prize lies not in real estate, but in the ecosystem acceleration unfolding across Fusionopolis and the expanding Biopolis complex.

Established contract research organisations like Charles River Laboratories have already expanded their footprint along Rochester Drive, capitalising on proximity to National University of Singapore researchers and the growing talent pipeline. Meanwhile, smaller players—clinical-stage biotech firms and synthetic biology startups—are securing subleases at premium rates, betting that clustering effects will accelerate their path to funding rounds and exit opportunities.

"The density of expertise here is unmatched in Southeast Asia," explains Arjun Rao, founder of a gene-editing startup now based in a shared lab facility at Biopolis. "Six months ago, we couldn't have afforded this kind of infrastructure access. Now, with the new government matching schemes for early-stage biotech, it's suddenly viable."

The Singapore Economic Development Board's revised biotech grant framework—which now covers up to 40 per cent of R&D costs for companies meeting certain commercialisation milestones—has unlocked investment gatekeeping that previously favoured only the most well-connected founders. Over 60 applications landed in the first quarter of 2026 alone, double the previous year's pace.

But advantages flow unevenly. Large pharmaceutical firms with existing Singapore operations—Roche, Takeda, GSK—are positioning subsidiary innovation labs within One-North, leveraging their balance sheets to snap up the most coveted lab spaces and attracting top talent away from smaller competitors. Rental costs for Grade-A laboratory facilities have risen to S$8–12 per square foot monthly, up from S$5.50 just two years ago.

The spillover benefits are visible elsewhere too. Hospitality providers around the district are upgrading offerings for visiting investors and international collaborators. Property consultants report heightened enquiries from venture funds seeking to establish regional hubs along Fusionopolis Drive and Morrison Road.

For Singapore's innovation narrative, One-North represents a deliberate concentration strategy: rather than scatter biotech investments islandwide, policy makers have bet on creating a defensible competitive advantage through density and co-location. Early movers benefit most. Latecomers face steeper entry costs and tighter space availability—a dynamic likely to persist through 2027.

This article was compiled by AI from the sources linked above and screened before publishing. See our editorial standards.